• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatment of Digital Ulcers and Reflux Oesophagitis in a Patient with Systemic Sclerosis: Increased Risk of Hepatotoxicity due to a Potential Drug-drug Interaction Between Bosentan and Vonoprazan.

作者信息

Kimura Ryoko, Sugita Kazunari, Sugihara Takaaki, Isomoto Hajime, Yamamoto Osamu

机构信息

Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago 683-8503, Japan.

出版信息

Acta Derm Venereol. 2021 Nov 24;101(11):adv00600. doi: 10.2340/actadv.v101.439.

DOI:10.2340/actadv.v101.439
PMID:34694420
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9455316/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ffc/9455316/ddb99776dce1/ActaDV-101-11-439-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ffc/9455316/ddb99776dce1/ActaDV-101-11-439-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ffc/9455316/ddb99776dce1/ActaDV-101-11-439-g001.jpg

相似文献

1
Treatment of Digital Ulcers and Reflux Oesophagitis in a Patient with Systemic Sclerosis: Increased Risk of Hepatotoxicity due to a Potential Drug-drug Interaction Between Bosentan and Vonoprazan.系统性硬化症患者指端溃疡和反流性食管炎的治疗：波生坦与沃克帕唑之间潜在的药物相互作用导致肝毒性风险增加。
Acta Derm Venereol. 2021 Nov 24;101(11):adv00600. doi: 10.2340/actadv.v101.439.
2
Bosentan: a review of its use in the management of digital ulcers associated with systemic sclerosis.波生坦：用于治疗系统性硬化症相关指端溃疡的综述
Drugs. 2009 Oct 1;69(14):2005-24. doi: 10.2165/10489160-000000000-00000.
3
Severe hepatotoxicity in a patient on bosentan upon addition of methotrexate: reversible with resumption of methotrexate without bosentan.波生坦治疗的患者加用甲氨蝶呤后出现严重肝毒性：停用波生坦后恢复甲氨蝶呤治疗，肝毒性可逆转。
J Clin Rheumatol. 2009 Mar;15(2):88-9. doi: 10.1097/RHU.0b013e31819bc71f.
4
Bosentan for digital ulcers in patients with systemic sclerosis.波生坦治疗系统性硬化症患者的手指溃疡。
J Dermatol. 2012 Jan;39(1):48-51. doi: 10.1111/j.1346-8138.2011.01299.x. Epub 2011 Sep 28.
5
Liver impairment after concomitant administration of bosentan and clarithromycin in systemic sclerosis.系统性硬化症患者同时服用波生坦和克拉霉素后出现肝功能损害。
Joint Bone Spine. 2010 Jan;77(1):81-2. doi: 10.1016/j.jbspin.2009.04.010. Epub 2009 Dec 22.
6
New hope for systemic sclerosis patients with digital ulcers.患有指端溃疡的系统性硬化症患者迎来新希望。
Curr Rheumatol Rep. 2005 Apr;7(2):127-8. doi: 10.1007/s11926-005-0064-1.
7
Effects of Bosentan in the Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: A Longitudinal, Multicenter, Uncontrolled Trial.波生坦治疗韩国系统性硬化症患者指端溃疡的疗效：一项纵向、多中心、非对照试验
J Clin Rheumatol. 2021 Dec 1;27(8):e599-e601. doi: 10.1097/RHU.0000000000001461.
8
[Digital ulcers in systemic sclerosis : A retrospective heath service study analysing treatment with bosentan and other vasoactive therapies].系统性硬化症中的指端溃疡：一项回顾性医疗服务研究，分析波生坦及其他血管活性疗法的治疗情况
Z Rheumatol. 2017 Apr;76(3):228-237. doi: 10.1007/s00393-016-0177-0.
9
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.系统性硬化症中的指端溃疡：通过口服内皮素受体拮抗剂波生坦治疗进行预防
Arthritis Rheum. 2004 Dec;50(12):3985-93. doi: 10.1002/art.20676.
10
[Bosentan for treatment of active digital ulcers in patients with systemic sclerosis].波生坦治疗系统性硬化症患者的活动性指端溃疡
Presse Med. 2006 Apr;35(4 Pt 1):587-92. doi: 10.1016/s0755-4982(06)74645-0.

本文引用的文献

1
Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan and .沃克帕唑基于细胞色素P450的药物相互作用及…… （原文不完整）
Front Pharmacol. 2020 Feb 14;11:53. doi: 10.3389/fphar.2020.00053. eCollection 2020.
2
Pharmacological Approach to Gastric Acid Suppression: Past, Present, and Future.胃酸抑制的药理学方法：过去、现在和未来。
Dig Dis. 2020;38(2):104-111. doi: 10.1159/000505204. Epub 2019 Dec 17.
3
The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease.钾离子竞争型酸阻滞剂在胃食管反流病治疗中的潜在作用。
Curr Opin Gastroenterol. 2019 Jul;35(4):344-355. doi: 10.1097/MOG.0000000000000543.
4
Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers.质子泵抑制剂（埃索美拉唑和沃诺拉赞）对环丙沙星（CYP2C19 底物）在健康志愿者体内处置的影响。
Br J Clin Pharmacol. 2019 Jul;85(7):1454-1463. doi: 10.1111/bcp.13914. Epub 2019 Apr 16.
5
Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases.强效钾离子竞争性酸阻滞剂：治疗酸相关性疾病的新时代。
J Neurogastroenterol Motil. 2018 Jul 30;24(3):334-344. doi: 10.5056/jnm18029.
6
Clinical drug-drug interactions of bosentan, a potent endothelial receptor antagonist, with various drugs: Physiological role of enzymes and transporters.
Gen Physiol Biophys. 2016 Jul;35(3):243-58. doi: 10.4149/gpb_2015050. Epub 2016 Apr 5.
7
Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.随机临床试验：新型钾离子竞争性酸阻滞剂沃克沙唑与兰索拉唑治疗糜烂性食管炎的疗效比较
Aliment Pharmacol Ther. 2016 Jan;43(2):240-51. doi: 10.1111/apt.13461. Epub 2015 Nov 11.
8
The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.一流的钾竞争性酸阻滞剂富马酸沃克索仑：药代动力学和药效学考量
Clin Pharmacokinet. 2016 Apr;55(4):409-18. doi: 10.1007/s40262-015-0326-7.
9
Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis.系统性硬化症患者的数字化溃疡愈合和预防的荟萃分析。
Arthritis Care Res (Hoboken). 2013 Sep;65(9):1460-71. doi: 10.1002/acr.22018.
10
Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.评价六种质子泵抑制剂对各种人细胞色素 P450 的抑制作用：重点关注细胞色素 P450 2C19。
Drug Metab Dispos. 2012 Sep;40(9):1698-711. doi: 10.1124/dmd.112.045575. Epub 2012 May 30.